|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ENTPD4 |
Gene summary for ENTPD4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ENTPD4 | Gene ID | 9583 |
| Gene name | ectonucleoside triphosphate diphosphohydrolase 4 | |
| Gene Alias | LALP70 | |
| Cytomap | 8p21.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9Y227 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9583 | ENTPD4 | LZE4T | Human | Esophagus | ESCC | 1.53e-11 | 1.67e-01 | 0.0811 |
| 9583 | ENTPD4 | LZE7T | Human | Esophagus | ESCC | 3.87e-09 | 2.33e-01 | 0.0667 |
| 9583 | ENTPD4 | LZE8T | Human | Esophagus | ESCC | 3.40e-12 | 3.11e-01 | 0.067 |
| 9583 | ENTPD4 | LZE24T | Human | Esophagus | ESCC | 6.55e-10 | 1.27e-01 | 0.0596 |
| 9583 | ENTPD4 | LZE21T | Human | Esophagus | ESCC | 2.07e-03 | 1.69e-01 | 0.0655 |
| 9583 | ENTPD4 | P1T-E | Human | Esophagus | ESCC | 3.34e-05 | 2.80e-01 | 0.0875 |
| 9583 | ENTPD4 | P2T-E | Human | Esophagus | ESCC | 5.51e-29 | 3.70e-01 | 0.1177 |
| 9583 | ENTPD4 | P4T-E | Human | Esophagus | ESCC | 1.91e-22 | 3.02e-01 | 0.1323 |
| 9583 | ENTPD4 | P5T-E | Human | Esophagus | ESCC | 7.90e-04 | 2.22e-02 | 0.1327 |
| 9583 | ENTPD4 | P8T-E | Human | Esophagus | ESCC | 1.36e-24 | 2.28e-01 | 0.0889 |
| 9583 | ENTPD4 | P9T-E | Human | Esophagus | ESCC | 4.01e-12 | 9.10e-02 | 0.1131 |
| 9583 | ENTPD4 | P10T-E | Human | Esophagus | ESCC | 8.13e-18 | 2.04e-01 | 0.116 |
| 9583 | ENTPD4 | P11T-E | Human | Esophagus | ESCC | 2.62e-08 | 2.51e-01 | 0.1426 |
| 9583 | ENTPD4 | P12T-E | Human | Esophagus | ESCC | 5.00e-10 | 1.18e-01 | 0.1122 |
| 9583 | ENTPD4 | P15T-E | Human | Esophagus | ESCC | 6.45e-06 | 7.30e-02 | 0.1149 |
| 9583 | ENTPD4 | P16T-E | Human | Esophagus | ESCC | 1.43e-21 | 2.28e-01 | 0.1153 |
| 9583 | ENTPD4 | P19T-E | Human | Esophagus | ESCC | 5.47e-04 | 4.06e-01 | 0.1662 |
| 9583 | ENTPD4 | P20T-E | Human | Esophagus | ESCC | 3.79e-16 | 2.84e-01 | 0.1124 |
| 9583 | ENTPD4 | P21T-E | Human | Esophagus | ESCC | 2.48e-19 | 1.39e-01 | 0.1617 |
| 9583 | ENTPD4 | P22T-E | Human | Esophagus | ESCC | 1.20e-14 | 2.10e-01 | 0.1236 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0034655110 | Esophagus | ESCC | nucleobase-containing compound catabolic process | 272/8552 | 407/18723 | 2.92e-18 | 2.90e-16 | 272 |
| GO:004670018 | Esophagus | ESCC | heterocycle catabolic process | 286/8552 | 445/18723 | 1.12e-15 | 7.47e-14 | 286 |
| GO:004427019 | Esophagus | ESCC | cellular nitrogen compound catabolic process | 288/8552 | 451/18723 | 3.03e-15 | 1.79e-13 | 288 |
| GO:001943918 | Esophagus | ESCC | aromatic compound catabolic process | 295/8552 | 467/18723 | 1.09e-14 | 5.98e-13 | 295 |
| GO:190136118 | Esophagus | ESCC | organic cyclic compound catabolic process | 307/8552 | 495/18723 | 9.99e-14 | 4.80e-12 | 307 |
| GO:0006753110 | Esophagus | ESCC | nucleoside phosphate metabolic process | 288/8552 | 497/18723 | 1.80e-08 | 3.50e-07 | 288 |
| GO:0019693111 | Esophagus | ESCC | ribose phosphate metabolic process | 234/8552 | 396/18723 | 4.24e-08 | 7.76e-07 | 234 |
| GO:0009117111 | Esophagus | ESCC | nucleotide metabolic process | 282/8552 | 489/18723 | 4.70e-08 | 8.50e-07 | 282 |
| GO:0009141111 | Esophagus | ESCC | nucleoside triphosphate metabolic process | 78/8552 | 112/18723 | 2.36e-07 | 3.59e-06 | 78 |
| GO:0009259111 | Esophagus | ESCC | ribonucleotide metabolic process | 224/8552 | 385/18723 | 4.41e-07 | 6.00e-06 | 224 |
| GO:0072521111 | Esophagus | ESCC | purine-containing compound metabolic process | 238/8552 | 416/18723 | 1.20e-06 | 1.49e-05 | 238 |
| GO:0009150111 | Esophagus | ESCC | purine ribonucleotide metabolic process | 213/8552 | 368/18723 | 1.40e-06 | 1.69e-05 | 213 |
| GO:0006163111 | Esophagus | ESCC | purine nucleotide metabolic process | 226/8552 | 396/18723 | 2.81e-06 | 3.21e-05 | 226 |
| GO:000919918 | Esophagus | ESCC | ribonucleoside triphosphate metabolic process | 61/8552 | 89/18723 | 1.07e-05 | 1.01e-04 | 61 |
| GO:000913219 | Esophagus | ESCC | nucleoside diphosphate metabolic process | 77/8552 | 124/18723 | 1.65e-04 | 1.09e-03 | 77 |
| GO:000918520 | Esophagus | ESCC | ribonucleoside diphosphate metabolic process | 66/8552 | 106/18723 | 4.21e-04 | 2.39e-03 | 66 |
| GO:00062203 | Esophagus | ESCC | pyrimidine nucleotide metabolic process | 35/8552 | 50/18723 | 4.33e-04 | 2.44e-03 | 35 |
| GO:00091473 | Esophagus | ESCC | pyrimidine nucleoside triphosphate metabolic process | 20/8552 | 25/18723 | 4.81e-04 | 2.69e-03 | 20 |
| GO:00725273 | Esophagus | ESCC | pyrimidine-containing compound metabolic process | 52/8552 | 82/18723 | 9.03e-04 | 4.61e-03 | 52 |
| GO:000913520 | Esophagus | ESCC | purine nucleoside diphosphate metabolic process | 63/8552 | 103/18723 | 1.10e-03 | 5.52e-03 | 63 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0414222 | Esophagus | ESCC | Lysosome | 102/4205 | 132/8465 | 5.11e-11 | 7.13e-10 | 3.65e-10 | 102 |
| hsa012325 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
| hsa002405 | Esophagus | ESCC | Pyrimidine metabolism | 41/4205 | 58/8465 | 9.14e-04 | 2.92e-03 | 1.49e-03 | 41 |
| hsa0414232 | Esophagus | ESCC | Lysosome | 102/4205 | 132/8465 | 5.11e-11 | 7.13e-10 | 3.65e-10 | 102 |
| hsa0123212 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
| hsa0024012 | Esophagus | ESCC | Pyrimidine metabolism | 41/4205 | 58/8465 | 9.14e-04 | 2.92e-03 | 1.49e-03 | 41 |
| hsa041422 | Liver | HCC | Lysosome | 100/4020 | 132/8465 | 2.32e-11 | 4.31e-10 | 2.40e-10 | 100 |
| hsa002402 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
| hsa012322 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
| hsa041423 | Liver | HCC | Lysosome | 100/4020 | 132/8465 | 2.32e-11 | 4.31e-10 | 2.40e-10 | 100 |
| hsa002403 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
| hsa012323 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ENTPD4 | SNV | Missense_Mutation | novel | c.369N>A | p.Met123Ile | p.M123I | Q9Y227 | protein_coding | deleterious(0.01) | possibly_damaging(0.833) | TCGA-AC-A3W6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| ENTPD4 | SNV | Missense_Mutation | c.1514N>T | p.Ser505Leu | p.S505L | Q9Y227 | protein_coding | tolerated(0.12) | benign(0.206) | TCGA-BH-A1EV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| ENTPD4 | SNV | Missense_Mutation | c.436C>G | p.Pro146Ala | p.P146A | Q9Y227 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-E2-A14V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| ENTPD4 | SNV | Missense_Mutation | rs759956146 | c.844N>A | p.Glu282Lys | p.E282K | Q9Y227 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
| ENTPD4 | SNV | Missense_Mutation | rs760898941 | c.1838N>T | p.Pro613Leu | p.P613L | Q9Y227 | protein_coding | deleterious_low_confidence(0.01) | benign(0.023) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ENTPD4 | SNV | Missense_Mutation | rs372875344 | c.1088C>T | p.Pro363Leu | p.P363L | Q9Y227 | protein_coding | deleterious(0) | benign(0.313) | TCGA-FU-A5XV-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| ENTPD4 | SNV | Missense_Mutation | c.883N>A | p.Glu295Lys | p.E295K | Q9Y227 | protein_coding | deleterious(0.01) | probably_damaging(0.969) | TCGA-A6-6649-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | SD | |
| ENTPD4 | SNV | Missense_Mutation | c.357N>G | p.Asp119Glu | p.D119E | Q9Y227 | protein_coding | tolerated(0.05) | possibly_damaging(0.466) | TCGA-AA-3489-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| ENTPD4 | SNV | Missense_Mutation | c.1019N>A | p.Arg340Lys | p.R340K | Q9Y227 | protein_coding | tolerated(0.3) | benign(0.007) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| ENTPD4 | SNV | Missense_Mutation | novel | c.1031N>T | p.Asn344Ile | p.N344I | Q9Y227 | protein_coding | tolerated(0.22) | benign(0.167) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |